Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo
J. Clin. Invest. Heather B. Adkins, et al. 112:575 doi:10.1172/JCI17788 [Go to this article.]

Figure 2
Anti-CFC mAb’s block Nodal signaling and Cripto-Alk4 interactions. (a) NCCIT cells were transfected with plasmids expressing (n2)₇-luciferase and Nodal (column 1) or (n2)₇-luciferase, FAST, and Nodal (columns 2–6). A27.F6.1 was added at 0, 1, 3, 10, or 30 μg/ml for 16 hours before luciferase reading (P < 0.001 for each dose). (b) Human 293-Alk4 cells were incubated with Cr-hFc or Cr-hFc prebound with mAb and assayed for binding by FACS using an anti-hFc PE-conjugated secondary mAb. The mean fluorescence intensity of Cr-hFc/mAb bound to 293-Alk4 cells is represented as a percentage of Cr-hFc binding with no mAb. (c) NCCIT cells were assayed for blocking of Cripto-Nodal signaling by A8.G3.5 at 10 μg/ml (P = 0.002) or 30 μg/ml (P = 0.05) as described in a